Jacobi Capital Management LLC Immuno Gen, Inc. Transaction History

Jacobi Capital Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$14.09 - $19.87 $140,900 - $198,700	-10,000 Reduced 37.74%	16,500 $261,000
Q2 2023 Aug 08, 2023	SELL	$3.75 - $20.05 $73,125 - $390,975	-19,500 Reduced 42.39%	26,500 $500,000
Q4 2022 Feb 13, 2023	SELL	$4.55 - $6.31 $6,825 - $9,465	-1,500 Reduced 3.16%	46,000 $228,000
Q2 2022 Aug 05, 2022	BUY	$3.15 - $5.76 $15,750 - $28,800	5,000 Added 11.76%	47,500 $214,000
Q1 2022 May 06, 2022	BUY	$4.26 - $7.48 $42,600 - $74,800	10,000 Added 30.77%	42,500 $202,000
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $14,557 - $19,111	2,900 Added 9.8%	32,500 $184,000
Q2 2021 Aug 12, 2021	BUY	$5.79 - $8.6 $12,159 - $18,060	2,100 Added 7.64%	29,600 $195,000
Q4 2020 Feb 08, 2021	BUY	$3.7 - $7.66 $55,500 - $114,900	15,000 Added 120.0%	27,500 $177,000
Q2 2020 Aug 04, 2020	BUY	$3.32 - $5.34 $41,417 - $66,616	12,475 Added 49900.0%	12,500 $58,000
Q2 2020 Jul 27, 2020	SELL	$3.32 - $5.34 $41,417 - $66,616	-12,475 Reduced 99.8%	25 $58,000
Q1 2018 May 03, 2018	SELL	$6.7 - $12.95 $16,750 - $32,375	-2,500 Reduced 16.67%	12,500 $127,000
Q2 2017 Aug 10, 2017	BUY	N/A	15,000	15,000 $110,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Jacobi Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Jacobi Capital Management LLC with notifications on news.